Harrow, INC

Harrow, Inc. reported a significant sequential revenue increase of 60% for Q2 2026, driven by strong performance in VEVYE and IHEEZO, and reiterated full-year guidance.

Harrow, Inc. announced its definitive agreement to acquire the global rights to TYRVAYA (varenicline solution) nasal spray from Viatris Inc., expanding its dry eye disease portfolio.

Harrow, Inc. has released a corporate presentation dated June 2026, intended for investor relations and outlining company information.

Harrow, Inc. announced its first quarter 2026 financial results, highlighting strong demand for key products like VEVYE, IHEEZO, and TRIESENCE, while addressing a non-recurring revenue adjustment impacting reported figures.

Harrow, Inc. announced the issuance of an additional $50 million in 8.625% Senior Notes due 2030 to fund general corporate purposes and growth initiatives.

Harrow, Inc. announced the pricing of a $50.0 million private offering of additional 8.625% Senior Notes due 2030 to fund general corporate purposes and growth initiatives.

Harrow Inc. announced its Q2 2026 financial results, showing an increase in total revenues driven by its branded segment, but also reporting a significant net loss and increased operating expenses.

Harrow, Inc. announced significant revenue increases and key strategic acquisitions in its Q3 2025 filing, alongside a major debt refinancing and new credit facility.

Harrow, Inc. reported significant revenue growth in its branded ophthalmology segment for the first half of 2025, alongside improved cash flow from operations, but faces substantial debt maturities in early 2026.

Harrow Inc. saw a revenue increase in Q1 2025, driven by strong sales of branded ophthalmology products, while navigating debt refinancing and regulatory considerations.

Harrow Inc. experienced a significant increase in product sales during the third quarter of 2024, but still reported a net loss due to increased operating expenses and interest costs.

Harrow Inc. saw a significant increase in product sales but reported a net loss for the second quarter of 2024, according to its latest financial report.

Harrow, Inc. reports significant revenue growth in its branded ophthalmic products for 2025, driven by increased marketing efforts for IHEEZO and VEVYE, alongside strategic acquisitions and debt refinancing.

Harrow, Inc. extends an employment offer to Amir Shojaei to serve as Chief Scientific Officer, effective January 6, 2025, with a focus on strengthening its scientific leadership.

Harrow, Inc.'s 10-K filing outlines the company's registered securities, including common stock and senior notes, along with details on capital structure, anti-takeover provisions, and debt obligations.

Amir Shojaei, CHIEF SCIENTIFIC OFFICER of Harrow, Inc., sold 11,250 shares of common stock on August 14, 2026 for $40.00 per share.

Adrienne L. Graves, a Director at Harrow Inc. (HROW), reported the acquisition of 1,000 shares of common stock on May 18, 2026.

Lauren P. Silvernail, a Director at Harrow, Inc., acquired 1,000 shares of common stock on May 18, 2026.

Amir Shojaei, Chief Scientific Officer of Harrow Inc., received a grant of 10,000 restricted stock units.

Harrow Inc. CEO Mark L. Baum acquired 10,000 shares of common stock in a series of transactions.

Andrew R. Boll, President and CFO of Harrow, Inc., acquired 3,500 shares of common stock through open market purchases.

Harrow, Inc. has filed a definitive proxy statement with the SEC.

Harrow, Inc. is set to hold its 2025 Annual Meeting of Stockholders on June 18, 2025, and is seeking stockholder approval for a new incentive stock and awards plan.

Harrow, Inc. has filed a definitive proxy statement with the SEC.

Harrow, Inc. announces its 2024 Annual Meeting of Stockholders to be held on June 14, 2024, outlining proposals for director elections, auditor ratification, and executive compensation advisory vote.

Harrow, Inc. CEO Mark L. Baum has increased his beneficial ownership in the company to 10.69% through the vesting and exercise of stock options, restricted stock units (RSUs), and performance share units (PSUs) as part of his compensation.

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, disclosing beneficial ownership of 2,400,000 shares of Harrow, Inc. common stock, representing 6.44% of the outstanding shares.

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, reporting beneficial ownership of 7.61% of Harrow, Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Harrow Inc. following an internal realignment.